Key facts
- Weight-loss medications like Wegovy and Ozempic contain semaglutide or tirzepatide, mimicking the GLP-1 hormone.
- These drugs suppress appetite and can reduce cravings for alcohol and nicotine by affecting the brain's reward response.
- Studies suggest these medications lead to fewer days of heavy drinking in individuals with alcohol use disorder.
- Users report a range of effects, from complete loss of alcohol cravings to nausea and reduced tolerance.
- While beneficial for some, the impact on alcohol consumption can negatively affect the social lives of others.
- Further research is required to establish the drugs' safety and efficacy for treating alcohol addiction.
Weight-loss medications containing semaglutide or tirzepatide, such as Wegovy and Ozempic, are increasingly being recognized for their impact on alcohol consumption. These drugs mimic the natural hormone GLP-1, which suppresses appetite and promotes satiety, aiding in weight loss. However, emerging research suggests they also affect the brain's reward pathways, potentially reducing cravings for substances like alcohol and nicotine.
Early studies indicate a significant link between these medications and decreased alcohol intake. A small-scale study published in 2025 found that participants with alcohol use disorder experienced reduced cravings while taking Ozempic. More recently, research from the University of Colorado Anschutz suggested that GLP-1 medications in pill form led to fewer days of heavy drinking among individuals with mild to moderate alcohol use disorder.
Users report a variety of experiences. Some, like Lisa Rees, have found the reduction in alcohol consumption to be a welcome benefit, noting they physically cannot drink as much as before. Others, such as Warren Thomas, have experienced a near-complete loss of appetite for alcohol, finding it refreshing to cut back without conscious effort. For these individuals, the medication has provided a way to moderate or eliminate alcohol intake, sometimes without even having previously considered their drinking problematic.
However, the effect is not universally positive. Recent graduate Faye Goodwin feels the medication has hampered her social life, experiencing nausea and acid reflux when she drinks. She has even delayed her medication doses to be able to consume alcohol socially, but finds it difficult to enjoy herself when experiencing adverse effects or feeling sober while friends drink.
While observational studies suggest a general decrease in alcohol consumption among those on weight-loss drugs, clinical trials have largely focused on individuals with diagnosed alcohol use disorder. Experts like Dr. Christian Hendershot note that data is accumulating rapidly, with some U.S. facilities already prescribing these medications off-label for alcohol use disorder. However, larger, longer-term studies are needed before regulatory approval for addiction treatment can be considered. Questions also remain about the affordability and safety of using these drugs for addiction treatment in individuals without obesity or diabetes, alongside potential side effects like pancreatitis.